MA54653A - Modulateurs du récepteur de cxcr7 pipéridine - Google Patents

Modulateurs du récepteur de cxcr7 pipéridine

Info

Publication number
MA54653A
MA54653A MA054653A MA54653A MA54653A MA 54653 A MA54653 A MA 54653A MA 054653 A MA054653 A MA 054653A MA 54653 A MA54653 A MA 54653A MA 54653 A MA54653 A MA 54653A
Authority
MA
Morocco
Prior art keywords
cxcr7
piperidine
receptor modulators
modulators
receptor
Prior art date
Application number
MA054653A
Other languages
English (en)
Other versions
MA54653B1 (fr
Inventor
Hamed Aissaoui
Philippe Guerry
Francois Lehembre
Julien Pothier
Laetitia Pouzol
Sylvia Richard-Bildstein
Shuguang Yuan
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA54653A publication Critical patent/MA54653A/fr
Publication of MA54653B1 publication Critical patent/MA54653B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MA54653A 2016-07-28 2017-07-27 Modulateurs du récepteur de cxcr7 pipéridine MA54653B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016068052 2016-07-28

Publications (2)

Publication Number Publication Date
MA54653A true MA54653A (fr) 2021-12-29
MA54653B1 MA54653B1 (fr) 2023-04-28

Family

ID=59656027

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45782A MA45782B1 (fr) 2016-07-28 2017-07-27 Modulateurs du récepteur de cxcr7 pipéridine
MA54653A MA54653B1 (fr) 2016-07-28 2017-07-27 Modulateurs du récepteur de cxcr7 pipéridine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA45782A MA45782B1 (fr) 2016-07-28 2017-07-27 Modulateurs du récepteur de cxcr7 pipéridine

Country Status (32)

Country Link
US (2) US10752620B2 (fr)
EP (2) EP3490986B1 (fr)
JP (2) JP6655754B2 (fr)
KR (2) KR102497095B1 (fr)
CN (2) CN110563717B (fr)
AR (2) AR109180A1 (fr)
AU (2) AU2017302079B2 (fr)
BR (1) BR112019001551A2 (fr)
CA (1) CA3032017C (fr)
CL (2) CL2019000169A1 (fr)
CY (1) CY1125016T1 (fr)
DK (2) DK3490986T3 (fr)
EA (2) EA202091262A1 (fr)
ES (2) ES2954152T3 (fr)
FI (1) FI3798217T3 (fr)
HR (2) HRP20211988T1 (fr)
HU (2) HUE057315T2 (fr)
IL (2) IL264424B (fr)
LT (2) LT3798217T (fr)
MA (2) MA45782B1 (fr)
MX (2) MX2019001042A (fr)
MY (1) MY198113A (fr)
NZ (1) NZ751006A (fr)
PH (1) PH12019500188A1 (fr)
PL (2) PL3798217T3 (fr)
PT (2) PT3490986T (fr)
RS (2) RS64130B1 (fr)
SG (2) SG11201900633XA (fr)
SI (2) SI3798217T1 (fr)
TW (3) TWI691494B (fr)
WO (1) WO2018019929A1 (fr)
ZA (1) ZA201901256B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007881A (es) * 2018-01-26 2022-06-02 Idorsia Pharmaceuticals Ltd Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3- carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopr opil)-amida.
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
CR20240051A (es) 2021-08-02 2024-03-18 Syngenta Crop Protection Ag Derivados de pirazol microbiocidas
MX2023013961A (es) * 2021-10-01 2023-12-11 Nextgen Bioscience Co Ltd Nuevos derivados de la piperidina y composiciones farmaceuticas que los contienen, para inhibir la autotaxina.
WO2023110871A1 (fr) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Dérivés de pyrazole microbiocides
EP4238970A1 (fr) * 2022-03-03 2023-09-06 InterAx Biotech AG Modulateurs de ackr3 et leurs utilisations
CN115403510B (zh) * 2022-08-11 2023-04-25 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途
WO2024105104A1 (fr) 2022-11-16 2024-05-23 Syngenta Crop Protection Ag Dérivés de tétrahydroisoquinoline microbicides
WO2024115546A1 (fr) 2022-11-30 2024-06-06 Syngenta Crop Protection Ag Compositions fongicides
WO2024115512A1 (fr) 2022-11-30 2024-06-06 Syngenta Crop Protection Ag Dérivés de tétrahydroisoquinoline microbiocides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102324A1 (en) * 2002-02-28 2004-05-27 Annis Gary David Heterocyclic diamide invertebrate pest control agents
WO2004050024A2 (fr) 2002-11-27 2004-06-17 Incyte Corporation Derives de la 3-aminopyrrolidine modulateurs des recepteurs de la chemoquine
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2005032490A2 (fr) 2003-10-08 2005-04-14 Bristol-Myers Squibb Company Diamines cycliques et derives comme inhibiteurs du facteur xa
BRPI0607756A2 (pt) * 2005-02-18 2010-05-18 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos
WO2010054006A1 (fr) * 2008-11-04 2010-05-14 Chemocentryx, Inc. Modulateurs du cxcr7
JP6094578B2 (ja) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
WO2013084241A1 (fr) * 2011-12-09 2013-06-13 Cadila Healthcare Limited Composés inhibiteurs de rénine
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
PT2925745T (pt) * 2012-11-29 2018-08-08 Chemocentryx Inc Antagonistas de cxcr7
CN105263924B (zh) 2013-05-30 2018-10-19 爱杜西亚制药有限公司 Cxcr7受体调节剂
AU2014315457B2 (en) 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2788848T3 (es) 2013-09-06 2020-10-23 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
WO2015044900A1 (fr) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Composés immunomodulateurs thérapeutiques
KR20170047397A (ko) * 2014-09-10 2017-05-04 에피자임, 인코포레이티드 치환된 피페리딘 화합물
WO2016087370A1 (fr) * 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Modulateurs du récepteur cxcr7
MX2020007881A (es) 2018-01-26 2022-06-02 Idorsia Pharmaceuticals Ltd Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3- carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopr opil)-amida.

Also Published As

Publication number Publication date
TWI691494B (zh) 2020-04-21
CY1125016T1 (el) 2023-03-24
IL264424B (en) 2021-08-31
JP2019142874A (ja) 2019-08-29
CN110563717A (zh) 2019-12-13
ZA201901256B (en) 2021-08-25
DK3490986T3 (da) 2022-03-07
AU2020204578B2 (en) 2022-03-10
IL264424A (en) 2019-02-28
EA037507B1 (ru) 2021-04-06
HRP20211988T1 (hr) 2022-03-18
AU2020204578A1 (en) 2020-07-30
RS62855B1 (sr) 2022-02-28
TW201932454A (zh) 2019-08-16
JP6655754B2 (ja) 2020-02-26
TWI683812B (zh) 2020-02-01
HRP20230313T1 (hr) 2023-05-12
IL282942B (en) 2022-01-01
PT3798217T (pt) 2023-05-23
CN109563085B (zh) 2022-08-09
BR112019001551A2 (pt) 2019-05-14
KR102497091B1 (ko) 2023-02-06
TWI691497B (zh) 2020-04-21
AU2017302079B2 (en) 2021-07-22
PT3490986T (pt) 2022-02-01
JP2019525927A (ja) 2019-09-12
CA3032017C (fr) 2023-04-18
PL3490986T3 (pl) 2022-04-04
SI3798217T1 (sl) 2023-05-31
WO2018019929A1 (fr) 2018-02-01
MY198113A (en) 2023-08-03
DK3798217T3 (da) 2023-05-22
TW201806940A (zh) 2018-03-01
KR20200092420A (ko) 2020-08-03
HUE062019T2 (hu) 2023-09-28
KR102497095B1 (ko) 2023-02-06
RS64130B1 (sr) 2023-05-31
KR20190034620A (ko) 2019-04-02
ES2905755T3 (es) 2022-04-12
CA3032017A1 (fr) 2018-02-01
MA45782B1 (fr) 2021-12-31
CN109563085A (zh) 2019-04-02
CN110563717B (zh) 2022-08-09
AU2017302079A1 (en) 2019-03-21
JP6655742B2 (ja) 2020-02-26
CL2019003281A1 (es) 2020-05-04
LT3798217T (lt) 2023-05-25
LT3490986T (lt) 2022-02-10
AR115662A2 (es) 2021-02-10
SI3490986T1 (sl) 2022-02-28
MA45782A (fr) 2019-06-05
MA54653B1 (fr) 2023-04-28
US20190169180A1 (en) 2019-06-06
US11306078B2 (en) 2022-04-19
NZ751006A (en) 2021-07-30
EP3490986A1 (fr) 2019-06-05
SG11201900633XA (en) 2019-02-27
EP3490986B1 (fr) 2021-11-24
TW201922738A (zh) 2019-06-16
FI3798217T3 (fi) 2023-05-03
PH12019500188A1 (en) 2019-10-21
EA202091262A1 (ru) 2020-08-13
US20200385373A1 (en) 2020-12-10
HUE057315T2 (hu) 2022-04-28
SG10201906942PA (en) 2019-09-27
IL282942A (en) 2021-06-30
AR109180A1 (es) 2018-11-07
EP3798217B1 (fr) 2023-02-22
EA201990388A1 (ru) 2019-08-30
ES2954152T3 (es) 2023-11-20
CL2019000169A1 (es) 2019-06-21
MX2021004000A (es) 2021-06-23
PL3798217T3 (pl) 2023-06-12
EP3798217A1 (fr) 2021-03-31
MX2019001042A (es) 2019-06-10
US10752620B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
MA43382A (fr) Modulateurs des récepteurs des chimiokines
MA54653A (fr) Modulateurs du récepteur de cxcr7 pipéridine
DK3359160T3 (da) Farnesoid x receptor modulatorer
MA53943A (fr) Modulateurs de ror-gamma
MA55328A (fr) Modulateurs de ror-gamma
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
MA42133A (fr) Modulateurs du ccr2
DK3107562T3 (da) P97-ids-fusionsproteiner
DK3322543T3 (da) Vibrerende aktuator
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
MA52555A (fr) Modulateurs du récepteur des oestrogènes
DK3819287T3 (da) Amorft tapentadolphosphat
CL2016002136A1 (es) Proteinas de fusión uti
CR20180079A (es) Moléculas de fusión
DK3126521T3 (da) HNF4G-RSPO2-fusionsgen
FR3024169B1 (fr) Element de construction
DE112014006862A5 (de) Membranaktor
FR3020647B1 (fr) Element de construction
DK3205802T3 (da) Begrænserarrangement
FR3018292B1 (fr) Module de construction du type gabion
FI20165103A (fi) Laituri
ITUA20164068A1 (it) Dispositivo manuale per piantumazione
FI10667U1 (fi) Laiturielementti
FR3021840B3 (fr) Ramasseuse de pierres
ES1121730Y (es) Canon de arcabuz